User menu

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Bibliographic reference Choong, Meng Ling ; Pecquet, Christian ; Pendharkar, Vishal ; Diaconu, Carmen C ; Yong, Jacklyn Wei Yan ; et. al. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.. In: Journal of Cellular and Molecular Medicine (Print) : a journal of translational medicine, Vol. 17, no.11, p. 1397-1409 (2013)
Permanent URL http://hdl.handle.net/2078.1/137917
  1. James Chloé, Ugo Valérie, Le Couédic Jean-Pierre, Staerk Judith, Delhommeau François, Lacout Catherine, Garçon Loïc, Raslova Hana, Berger Roland, Bennaceur-Griscelli Annelise, Villeval Jean Luc, Constantinescu Stefan N., Casadevall Nicole, Vainchenker William, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, 10.1038/nature03546
  2. Kralovics Robert, Passamonti Francesco, Buser Andreas S., Teo Soon-Siong, Tiedt Ralph, Passweg Jakob R., Tichelli Andre, Cazzola Mario, Skoda Radek C., A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders, 10.1056/nejmoa051113
  3. Levine Ross L., Wadleigh Martha, Cools Jan, Ebert Benjamin L., Wernig Gerlinde, Huntly Brian J.P., Boggon Titus J., Wlodarska Iwona, Clark Jennifer J., Moore Sandra, Adelsperger Jennifer, Koo Sumin, Lee Jeffrey C., Gabriel Stacey, Mercher Thomas, D’Andrea Alan, Fröhling Stefan, Döhner Konstanze, Marynen Peter, Vandenberghe Peter, Mesa Ruben A., Tefferi Ayalew, Griffin James D., Eck Michael J., Sellers William R., Meyerson Matthew, Golub Todd R., Lee Stephanie J., Gilliland D. Gary, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, 10.1016/j.ccr.2005.03.023
  4. Baxter E Joanna, Scott Linda M, Campbell Peter J, East Clare, Fourouclas Nasios, Swanton Soheila, Vassiliou George S, Bench Anthony J, Boyd Elaine M, Curtin Natasha, Scott Mike A, Erber Wendy N, Green Anthony R, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, 10.1016/s0140-6736(05)71142-9
  5. Levine Ross L., Pardanani Animesh, Tefferi Ayalew, Gilliland D. Gary, Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders, 10.1038/nrc2210
  6. Vainchenker William, Dusa Alexandra, Constantinescu Stefan N., JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies, 10.1016/j.semcdb.2008.07.002
  7. Pikman Yana, Lee Benjamin H, Mercher Thomas, McDowell Elizabeth, Ebert Benjamin L, Gozo Maricel, Cuker Adam, Wernig Gerlinde, Moore Sandra, Galinsky Ilene, DeAngelo Daniel J, Clark Jennifer J, Lee Stephanie J, Golub Todd R, Wadleigh Martha, Gilliland D. Gary, Levine Ross L, MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, 10.1371/journal.pmed.0030270
  8. Pardanani A. D., Levine R. L., Lasho T., Pikman Y., Mesa R. A., Wadleigh M., Steensma D. P., Elliott M. A., Wolanskyj A. P., Hogan W. J., McClure R. F., Litzow M. R., Gilliland D. G., Tefferi A., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, 10.1182/blood-2006-04-018879
  9. Pecquet C., Staerk J., Chaligne R., Goss V., Lee K. A., Zhang X., Rush J., Van Hees J., Poirel H. A., Scheiff J.-M., Vainchenker W., Giraudier S., Polakiewicz R. D., Constantinescu S. N., Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor, 10.1182/blood-2008-10-183558
  10. Staerk J., An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor, 10.1182/blood-2005-06-2600
  11. Ma Xiaomei, Vanasse Gary, Cartmel Brenda, Wang Yun, Selinger H. Andrew, Prevalence of polycythemia vera and essential thrombocythemia, 10.1002/ajh.21129
  12. Mesa Ruben A., Silverstein Murray N., Jacobsen Steven J., Wollan Peter C., Tefferi Ayalew, Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995, 10.1002/(sici)1096-8652(199905)61:1<10::aid-ajh3>3.0.co;2-i
  13. Mesa Ruben A., New Drugs for the Treatment of Myelofibrosis, 10.1007/s11899-009-0037-y
  14. Verstovsek Srdan, Mesa Ruben A., Gotlib Jason, Levy Richard S., Gupta Vikas, DiPersio John F., Catalano John V., Deininger Michael, Miller Carole, Silver Richard T., Talpaz Moshe, Winton Elliott F., Harvey Jimmie H., Arcasoy Murat O., Hexner Elizabeth, Lyons Roger M., Paquette Ronald, Raza Azra, Vaddi Kris, Erickson-Viitanen Susan, Koumenis Iphigenia L., Sun William, Sandor Victor, Kantarjian Hagop M., A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, 10.1056/nejmoa1110557
  15. Harrison Claire, Kiladjian Jean-Jacques, Al-Ali Haifa Kathrin, Gisslinger Heinz, Waltzman Roger, Stalbovskaya Viktoriya, McQuitty Mari, Hunter Deborah S., Levy Richard, Knoops Laurent, Cervantes Francisco, Vannucchi Alessandro M., Barbui Tiziano, Barosi Giovanni, JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, 10.1056/nejmoa1110556
  16. Lu Xiaohui, Huang Lily Jun-Shen, Lodish Harvey F., Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F, 10.1074/jbc.m707125200
  17. Damen Jacqueline E., Cutler Robert L., Jiao Huaiyuan, Yi Taolin, Krystal Gerald, Phosphorylation of Tyrosine 503 in the Erythropoietin Receptor (EpR) Is Essential for Binding the P85 Subunit of Phosphatidylinositol (PI) 3-Kinase and for EpR-associated PI 3-Kinase Activity, 10.1074/jbc.270.40.23402
  18. Klingmuller U., Wu H., Hsiao J. G., Toker A., Duckworth B. C., Cantley L. C., Lodish H. F., Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors, 10.1073/pnas.94.7.3016
  19. Miyakawa Yoshitaka, Rojnuckarin Ponlapat, Habib Tania, Kaushansky Kenneth, Thrombopoietin Induces Phosphoinositol 3-Kinase Activation through SHP2, Gab, and Insulin Receptor Substrate Proteins in BAF3 Cells and Primary Murine Megakaryocytes, 10.1074/jbc.m002633200
  20. Kamishimoto Jun, Tago Kenji, Kasahara Tadashi, Funakoshi-Tago Megumi, Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation, 10.1016/j.cellsig.2011.01.009
  21. Rane Sushil G, Reddy E Premkumar, Janus kinases: components of multiple signaling pathways, 10.1038/sj.onc.1203925
  22. HEINRICH Peter C., BEHRMANN Iris, HAAN Serge, HERMANNS Heike M., MÜLLER-NEWEN Gerhard, SCHAPER Fred, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, 10.1042/bj20030407
  23. Foster F. M., The phosphoinositide (PI) 3-kinase family, 10.1242/jcs.00609
  24. Vanhaesebroeck Bart, Guillermet-Guibert Julie, Graupera Mariona, Bilanges Benoit, The emerging mechanisms of isoform-specific PI3K signalling, 10.1038/nrm2882
  25. Tefferi Ayalew, Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms, 10.1056/nejme1115119
  26. Koppikar Priya, Bhagwat Neha, Kilpivaara Outi, Manshouri Taghi, Adli Mazhar, Hricik Todd, Liu Fan, Saunders Lindsay M., Mullally Ann, Abdel-Wahab Omar, Leung Laura, Weinstein Abby, Marubayashi Sachie, Goel Aviva, Gönen Mithat, Estrov Zeev, Ebert Benjamin L., Chiosis Gabriela, Nimer Stephen D., Bernstein Bradley E., Verstovsek Srdan, Levine Ross L., Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy, 10.1038/nature11303
  27. Kvasnicka, Haematologica, 98, Abstract S591 (2013)
  28. Vannucchi, Haematologica, 98, Abstract S1111 (2013)
  29. Verstovsek, Blood (ASH Annual Meeting Abstracts), 120, Abstract 800 (2012)
  30. Huang Lily Jun-shen, Constantinescu Stefan N., Lodish Harvey F., The N-Terminal Domain of Janus Kinase 2 Is Required for Golgi Processing and Cell Surface Expression of Erythropoietin Receptor, 10.1016/s1097-2765(01)00401-4
  31. Seubert Nadine, Royer Yohan, Staerk Judith, Kubatzky Katharina F, Moucadel Virginie, Krishnakumar Shyam, Smith Steven O, Constantinescu Stefan N, Active and Inactive Orientations of the Transmembrane and Cytosolic Domains of the Erythropoietin Receptor Dimer, 10.1016/s1097-2765(03)00389-7
  32. Pecquet C., Diaconu C. C., Staerk J., Girardot M., Marty C., Royer Y., Defour J.-P., Dusa A., Besancenot R., Giraudier S., Villeval J.-L., Knoops L., Courtoy P. J., Vainchenker W., Constantinescu S. N., Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes, 10.1182/blood-2011-08-372524
  33. Chou Ting-Chao, Talalay Paul, Analysis of combined drug effects: a new look at a very old problem, 10.1016/0165-6147(83)90490-x
  34. Chou Ting-Chao, Talalay Paul, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, 10.1016/0065-2571(84)90007-4
  35. Marty C., Lacout C., Martin A., Hasan S., Jacquot S., Birling M.-C., Vainchenker W., Villeval J.-L., Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice, 10.1182/blood-2009-12-257063
  36. García-Martínez Juan M., Moran Jennifer, Clarke Rosemary G., Gray Alex, Cosulich Sabina C., Chresta Christine M., Alessi Dario R., Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR), 10.1042/bj20090489
  37. Guglielmelli P., Barosi G., Rambaldi A., Marchioli R., Masciulli A., Tozzi L., Biamonte F., Bartalucci N., Gattoni E., Lupo M. L., Finazzi G., Pancrazzi A., Antonioli E., Susini M. C., Pieri L., Malevolti E., Usala E., Occhini U., Grossi A., Caglio S., Paratore S., Bosi A., Barbui T., Vannucchi A. M., , Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis, 10.1182/blood-2011-01-330563
  38. Quintas-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P. A., Caulder E., Wen X., Li Y., Waeltz P., Rupar M., Burn T., Lo Y., Kelley J., Covington M., Shepard S., Rodgers J. D., Haley P., Kantarjian H., Fridman J. S., Verstovsek S., Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, 10.1182/blood-2009-04-214957
  39. Andraos Rita, Qian Zhiyan, Bonenfant Débora, Rubert Joëlle, Vangrevelinghe Eric, Scheufler Clemens, Marque Fanny, Régnier Catherine H., De Pover Alain, Ryckelynck Hugues, Bhagwat Neha, Koppikar Priya, Goel Aviva, Wyder Lorenza, Tavares Gisele, Baffert Fabienne, Pissot-Soldermann Carole, Manley Paul W., Gaul Christoph, Voshol Hans, Levine Ross L., Sellers William R., Hofmann Francesco, Radimerski Thomas, Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent, 10.1158/2159-8290.cd-11-0324
  40. Khan I, Huang Z, Wen Q, Stankiewicz M J, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke C M, Lasho T L, Koppikar P, Pardanani A, Stein B, Altman J K, Levine R L, Tefferi A, Crispino J D, AKT is a therapeutic target in myeloproliferative neoplasms, 10.1038/leu.2013.167
  41. Chou T.-C., Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method, 10.1158/0008-5472.can-09-1947
  42. Harrington K. J., Hingorani M., Tanay M. A., Hickey J., Bhide S. A., Clarke P. M., Renouf L. C., Thway K., Sibtain A., McNeish I. A., Newbold K. L., Goldsweig H., Coffin R., Nutting C. M., Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck, 10.1158/1078-0432.ccr-10-0196
  43. Mihu Coralia N., Kassis Christelle, Ramos Elizabeth R., Jiang Ying, Hachem Ray Y., Raad Issam I., Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?, 10.1002/cncr.25312
  44. Chen Yi, Alvarez Edwin A., Azzam Diana, Wander Seth A., Guggisberg Natalia, Jordà Mercè, Ju Zhenlin, Hennessy Bryan T., Slingerland Joyce M., Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo, 10.1007/s10549-010-1024-7
  45. Kong Dexin, Dan Shingo, Yamazaki Kanami, Yamori Takao, Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39, 10.1016/j.ejca.2010.01.005
  46. Levine D. A., Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers, 10.1158/1078-0432.ccr-04-2142
  47. Jia, Nature, 454, 776 (2008)
  48. Sasaki T., Function of PI3K in Thymocyte Development, T Cell Activation, and Neutrophil Migration, 10.1126/science.287.5455.1040
  49. Sadhu C., Masinovsky B., Dick K., Sowell C. G., Staunton D. E., Essential Role of Phosphoinositide 3-Kinase   in Neutrophil Directional Movement, 10.4049/jimmunol.170.5.2647
  50. Fiskus W., Verstovsek S., Manshouri T., Smith J. E., Peth K., Abhyankar S., McGuirk J., Bhalla K. N., Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells, 10.1158/1535-7163.mct-12-0862
  51. Besancenot Rodolphe, Chaligné Ronan, Tonetti Carole, Pasquier Florence, Marty Caroline, Lécluse Yann, Vainchenker William, Constantinescu Stefan N., Giraudier Stéphane, A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation, 10.1371/journal.pbio.1000476
  52. Nguyen Melody H.-H., Ho Jenny M.-Y., Beattie Bryan K., Barber Dwayne L., TEL-JAK2 Mediates Constitutive Activation of the Phosphatidylinositol 3′-Kinase/Protein Kinase B Signaling Pathway, 10.1074/jbc.m103100200
  53. Carvalho Carla R. O., Carvalheira José B. C., Lima Maria H. M., Zimmerman Suzana F., Caperuto Luciana C., Amanso Angélica, Gasparetti Alessandra L., Meneghetti Vainer, Zimmerman Leonardo F., Velloso Licio A., Saad Mario J. A., Novel Signal Transduction Pathway for Luteinizing Hormone and Its Interaction with Insulin: Activation of Janus Kinase/Signal Transducer and Activator of Transcription and Phosphoinositol 3-Kinase/Akt Pathways, 10.1210/en.2002-220706
  54. Gross E. R., The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3beta, 10.1152/ajpheart.00003.2006
  55. Harir N., Pecquet C., Kerenyi M., Sonneck K., Kovacic B., Nyga R., Brevet M., Dhennin I., Gouilleux-Gruart V., Beug H., Valent P., Lassoued K., Moriggl R., Gouilleux F., Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias, 10.1182/blood-2006-01-029918
  56. Abe Miyuki, Funakoshi-Tago Megumi, Tago Kenji, Kamishimoto Jun, Aizu-Yokota Eriko, Sonoda Yoshiko, Kasahara Tadashi, The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice, 10.1016/j.intimp.2009.03.011
  57. Verstovsek Srdan, Kantarjian Hagop, Mesa Ruben A., Pardanani Animesh D., Cortes-Franco Jorge, Thomas Deborah A., Estrov Zeev, Fridman Jordan S., Bradley Edward C., Erickson-Viitanen Susan, Vaddi Kris, Levy Richard, Tefferi Ayalew, Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, 10.1056/nejmoa1002028
  58. Pardanani Animesh, Gotlib Jason R., Jamieson Catriona, Cortes Jorge E., Talpaz Moshe, Stone Richard M., Silverman Michael H., Gilliland D. Gary, Shorr Jolene, Tefferi Ayalew, Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis, 10.1200/jco.2010.32.8021
  59. Verstovsek S., Kantarjian H. M., Estrov Z., Cortes J. E., Thomas D. A., Kadia T., Pierce S., Jabbour E., Borthakur G., Rumi E., Pungolino E., Morra E., Caramazza D., Cazzola M., Passamonti F., Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls, 10.1182/blood-2012-02-414631